{"id":1441624,"date":"2023-12-01T12:20:00","date_gmt":"2023-12-01T17:20:00","guid":{"rendered":"https:\/\/bugaluu.com\/news\/?p=1441624"},"modified":"2023-12-01T12:20:00","modified_gmt":"2023-12-01T17:20:00","slug":"pfizer-tumbles-after-abandoning-weight-loss-pill","status":"publish","type":"post","link":"https:\/\/bugaluu.com\/news\/pfizer-tumbles-after-abandoning-weight-loss-pill\/1441624\/","title":{"rendered":"Pfizer Tumbles After Abandoning Weight-Loss Pill"},"content":{"rendered":"

Pfizer Tumbles After Abandoning Weight-Loss Pill<\/span><\/p>\n

\n

With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it halted development of its experimental weight-loss pill after a high rate of side effects<\/strong> appeared in a mid-stage study.<\/p>\n

<\/a><\/p>\n

More than half of patients in the study had to stop taking\u00a0danuglipron<\/strong>\u00a0due to nausea and vomiting, according to a statement Friday.<\/p>\n

While the most common adverse events in the study were mild, nausea was seen in up to 73% of patients, vomiting in up to 47% and diarrhea in as much as 25%<\/strong>.<\/p>\n

Pfizer will continue developing a once-daily version of the pill in hopes that it may improve its tolerability profile.<\/p>\n

Pfizer had hoped to follow Eli Lilly and Novo Nordisk’s lead (both of which provide the shot-based GLP-1 agonists<\/strong> that have made so much news this year) and driven massive outperformance…<\/p>\n

<\/a><\/p>\n

Pfizer and\u00a0AstraZeneca saw pills as a way to make inroads<\/strong> into a market projected to reach $100 billion within seven years. Maybe not so much now…<\/p>\n

Pfizer CEO Albert Bourla has said that oral weight-loss drugs will capture\u00a0a third\u00a0of the obesity market.<\/p>\n

The company had pinned its weight-loss hopes on danuglipron after discontinuing another experimental obesity drug in June\u00a0due to safety concerns.<\/strong><\/p>\n

Pfizer shares are down around 4% in the pre-market, back near their lowest since March 2020 on the back of this news…<\/p>\n

<\/a><\/p>\n

Presumably, they did not have a liability waiver this time…<\/p>\n<\/div>\n

Tyler Durden<\/a><\/span>
\nFri, 12\/01\/2023 – 07:20<\/span><\/p>\n

\u200bhttps:\/\/www.zerohedge.com\/medical\/pfizer-tumbles-after-abandoning-weight-loss-pill<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

Pfizer Tumbles After Abandoning Weight-Loss Pill With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1441624","post","type-post","status-publish","format-standard","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1441624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/comments?post=1441624"}],"version-history":[{"count":0,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1441624\/revisions"}],"wp:attachment":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media?parent=1441624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/categories?post=1441624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/tags?post=1441624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}